<p>Close up of a middle aged woman dressed in a blazer, sitting down while looking at another person in the foreground.</p>

Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Letter from the CEO

First steps taken towards late-stage development of vididencel

In the first quarter of 2024, Mendus made significant progress with its lead program vididencel in acute myeloid leukemia (AML).

To read the full letter from the CEO, please click here.

Rights Issue and Directed Issue 2023

You will find all relevant information that are published in connection with the proposed rights issue and directed issue in Mendus on this page.

Update on Vididencel Program – Webcast and On-Site Event

Mendus provided an update on its lead program vididencel on Tuesday, June 27, 2023. The update took place in an online event and, separately, on-site at the company’s headquarters in Stockholm, Sweden.

The replay of the online event is accessible via the link below.

Vididencel Development Update – Webcast Replay

Latest Company Presentation

View the latest company presentation


ASH 2022 Webcast

Watch the replay


Mendus KOL Event – November 2022

Watch the replay


Latest press releases



<p>Image of old buildings by a dock with boats laying in the water in the foreground.</p>

Head Office

Västra Trädgårdsgatan 15
111 53 Stockholm

<p>City image from a walkway, with a church and tall buildings in the background.</p>

R&D Offices

Emmy Noetherweg 2K
2333 BK Leiden
The Netherlands

<p>Overview image of a city, shot in low sunlight from a far distance.</p>

Gothenburg Office

Mendus C/O AstraZeneca BioventureHub
Pepparedsleden 1
431 83 Mölndal